FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion–Mutated NSCLC
... of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
The FDA also ...
... of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
The FDA also ...
... with the addition of nivolumab to chemotherapy in patients with EGFR -mutant metastatic non–small cell lung cancer (NSCLC) after ...
Dr. Sun turned to targeted therapies for lung cancer and focused on the third-generation EGFR tyrosine kinase inhibitor osimertinib. ...
... /osimertinib in previously untreated patients with advanced EGFR -mutant non–small cell lung cancer (NSCLC).
Jordi Remon, MD, PhD ...
... for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with tumors having EGFR exon 19 deletions or exon ...
... non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration (FDA)- ...
Pretreated Melanoma
Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC
Novel CAR T ...
... in the United States
Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer
EGFR </em ...
... of lung cancer.
Early clinical trial results show that sunvozertinib is effective and well-tolerated in patients with EGFR exon 20 ...
... first research results on CKD-703, a new drug candidate for non-small cell lung cancer, at the American Association for Cancer Research ...